Na Cocer Peptides bin rayt am 
13 dez bifo
ƆL DI ATIKUL ƐN PRODƆKT INFƆMƐSHƆN WE DƐN GI NA DIS WƐBSAYT NA FƆ ƆL FƆ DI INFƆMƐSHƆN ƐN FƆ EDYUKESHƆN.
Di prɔdak dɛn we dɛn gi na dis wɛbsayt na fɔ in vitro risach nɔmɔ. in vitro risach (Latin: *in glas*, we min insay glas) dεn de du am ausayd mכtalman bכdi. Dɛn prɔdak ya nɔto famasitik, dɛn nɔ gɛt di aprɔval frɔm di US Food and Drug Administration (FDA), ɛn dɛn nɔ fɔ yuz dɛn fɔ protɛkt, trit, ɔ mɛn ɛni mɛrɛsin, sik, ɔ sik. Di lɔ nɔ gri fɔ mek dɛn put dɛn tin ya insay mɔtalman ɔ animal bɔdi ɛni we.
Ovaviu fɔ GLP-1
GLP-1 na nyu glukagכn lεk pεptida-1 rεsεptכr agonist (GLP-1 RA). glukagon lεk pεptida-1 (GLP-1) na כmon we di mכtalman bכdi de kכl nכmal wan we de ple imכtant rol fכ rεgεl di glukכs na di bכdi. we di blכd glukכs lεvεl go כp, di GLP-1 de kכmכt εn i de rεgεl di blכd glukכs lεvεl tru difrεn mεkanism dεm. Bɔt pan di wan dɛn we gɛt dayabitis, bɔku tɛm di GLP-1 sekreshɔn nɔ kin du ɔ di ifɛkt dɛn we i kin gɛt nɔ kin du. GLP-1 de biεn di GLP-1 rεsεpכta dεm, we de miks di fysiolojikal ifekt dεm we GLP-1 de gi, we de mek i de εksyεrt di tεrapi ifekt dεm fכ mεtabolism εn wet mεnejmεnt.
Fig 1 Tritmɛnt fɔ fat ɛn di impak we dɛn gɛt pan di wet we pɔsin de lɔs
Di Rol we GLP-1 de ple pan Dayabitis Tritmɛnt
Fɔ mek di insulin sekreshɔn
כnda di fysiolojikal kכndishכn dεm, we di blכd glukכs lεvεl de go כp, di εnteroεndokrin sεl dεm na di intestin de sekret GLP-1. GLP-1 de biεn di GLP-1 rεsεpכta dεm na di sεf pan di pankrεas β sεl dεm, we de aktibכt wan siriכs signal path fכ inkrεs insulin sekreshכn. GLP-1 kin spεshal biεn bak to GLP-1 rεsεpכta dεm na di sεf fכ pankrεas β sεl dεm, we de mek insulin sekreshכn insay wan we we dipεnd pan glukכs kכnsantreshכn. dis min se we di blכd glukכs lεvεl go כp, GLP-1 de εfεktiv fכ protεkt insulin rilis fכ lכs di blכd glukכs lεvεl; we di blכd glukכs lεvεl de insay di nכmal rεnj, in ifekt fכ protεkt insulin sekreshכn de wik, we de rεdכks di risk fכ haypoglycemia. Stɔdi dɔn sho se afta dɛn dɔn trit di sikman dɛn wit GLP-1, di insulin we de kɔmɔt na di sikman dɛn kin bɛtɛ, ɛn dɛn kin kɔntrol di glukɔs we de na di blɔd fayn fayn wan.
Figure 2: Wan apstrim weit-sεntrik aprכch vεrs mכr dכwnstrכm, glukכs-sεntrik, εn kכdiכmεtabolik aprכch. di tεrapi dεm we de bays pan inkrεtin dεn dכn כlrεdi aktif na di mכst כpstrim stεp.
difrεnt frכm tradishכnal insulin sekretagכg dεm, lεk sulfonylureas, we de kכntinyu fכ mek insulin sekreshכn i nכ mata di blכd glukכs lεvεl εn kin inkrεs di risk fכ haypoglycemia, GLP-1 in glukoz-kכnsantreshכn-dipεndεnt insulin sekreshכn prכpati dεm de mek i ebul fכ lכs di blɔd glukכs lεvεl fayn fayn wan we i de ridyus di insidεns fכ haypoglycemia, we de gi wan saf εn mכr ifektiv bכdi glukכs kכntrכl opshכn fכ di mεtabolism pasεnshכn dεm.
Inhibishכn fכ glukagon sekreshכn
Glucagon na כmon we di pankrεas α sεl dεm de kכl we de εlevεt di glukכs lεvεl na di bכdi, we de akt opכsite to insulin. Insay di wan dɛn we gɛt dayabitis, bɔku tɛm dɛn nɔ kin stɔp di glukoz we de kɔmɔt na di bɔdi ivin we di glukɔs we de na di blɔd go ɔp. GLP-1 de akt pan GLP-1 risεptor dεm pan pankrεas α sεl dεm fכ inhεbit glukagon sekreshכn. we di glukoz sekreshכn dכn dכn, di liva in glycogenolysis εn gluconeogenesis prכsεs dεm de inhεbit, we de ridyus di εndojεnik glukכs prodakshכn εn fכ lכs di bכdi glukכs lεvεl mכr. sayɛnsman dεm dכn kכnfכm se insay tayp 2 mεtabolism pasεnshכn dεm we dεn trit wit GLP-1, di plasma glukכs lεvεl dεm de dכn bכku bכku wan, we de ridyus di hεpatik glukכs autput εn ple implεnt rol fכ stεbyul di blכd glukכs lεvεl.
Dilay fɔ ɛmti di gastric
GLP-1 de akt pan GLP-1 risεptor dεm na di gεstrointestinal trakt fכ slo di gεstrik εmpti. We di bɛlɛ ɛmti kwik kwik wan, dat kin mek di it go insay di smɔl intestin kwik kwik wan, we kin mek di glukɔs we de na di blɔd go ɔp kwik kwik wan. bay we dεn de delay di gεstrik εmpti, di it de de na di bεlε fכ lכng tεm εn i de go insay di sכmכl intestin sloslo, we de mek di glukכs de tek mכr sכmtεm sכmtεm εn i nכ de mek di blכd glukכs lεvεl go shap shap afta i it. dis ifekt de εp fכ mεnten stebul postprandial bכdi glukכs lεvεl εn rεdכks di bכdi glukכs fכlt. Insay sɔm klinik trayal dɛn, di pasɛnt dɛn we dɛn trit wit GLP-1 bin ɛkspiriɛns wan big ridɔkshɔn pan di postprandial blɔd glukɔs pik ɛn smɔl smɔl blɔd glukɔs fluktueshɔn, we impruv di ɔvala blɔd glukɔs kɔntrol kwaliti. Apat frɔm dat, di delay we di gastric ɛmti kin mek pɔsin fil se i ful-ɔp, we kin ɛp fɔ ridyus di it we i de it ɛn dat kin ɛp fɔ kɔntrol di glukɔs na di blɔd ɛn fɔ manej di wet frɔm ɔda angle.
Fig 3: Mεkanism fכ GLP-1 fכ di Manejmεnt fכ Obesiti
Improving β-Sεl Fכnshכn
di krכnik haypa glycemia kin pwεl di pankrεas β sεl dεm, we kin mek di fכnshכn dεklin sכmtεm. GLP-1 nכ de כnli lכs di blכd shuga bay we i de mek insulin sekreshכn bכt i de protεkt εn rεpair pankrεas β sεl dεm, we de mek di β sεl dεm wok fayn. sayɛns stכdi dεn sho se GLP-1 kin aktibכt sכm intasεlulyar signal path dεm fכ promuot β-sεl proliferashכn, inhεbit β-sεl apoptosis, we de inkrεs di nכmba εn fכnshכn fכ β-sεl dεm. insay animal εkspεriεns εn sכm klinik stכdi dεm, dεn si se afta dεn yuz GLP-1, di insulin sekreshכn kapasiti fכ β sεl dεm bin εnhans, εn insulin rεsistεns bin impruv. Dis na big minin fɔ di lɔng tɛm tritmɛnt fɔ tayp 2 mɛtabolism, as i de ɛp fɔ slo di sik ɛn ridyus di risk fɔ gɛt dayabitik kɔmplikeshɔn.
Aplikeshɔn fɔ GLP-1 insay Dayabitis Tritmɛnt
GLP-1 gεt difrεn aplikεshכn mεtכd dεm na mεtabolism tritmεnt. Fɔ nyu tayp 2 mɛtabolism pasɛnt dɛn we dɛn dɔn no, if di blɔd glukɔs lɛvɛl nɔ rili ɛlevɛt ɛn nɔ klia akyu kɔmplikeshɔn ɔ ɔda siriɔs kɔmɔrɔbiditi nɔ de, dɛn kin tink bɔt wan tritmɛnt wit GLP-1. Klinik stכdi dεm sho se sכm nyu sik pipul dεm we dεn nכ no di sik bin gεt bכku dεkrεshכn pan hεmoglobin A1c (HbA1c) lεvεl εn weit lכs afta wan tεm we dεn bin tek wan tεrapi. Fɔ ɛgzampul, insay di PIONEER siriɔs stɔdi, di pasɛnt dɛn we dɛn trit wit ɔral GLP-1 monotɛrapi bin ɛkspiriɛns wan signifyant ridɔkshɔn pan HbA1c lɛvɛl kɔmpia to di plasɛbo grup, wit gud sef ɛn tolɛrabiliti. Di bɛnifit fɔ wan tritmɛnt na dat i de avɔyd di risk fɔ mek di mɛrɛsin dɛn we gɛt fɔ du wit kɔmbayn tɛrapi, ɛn di we aw dɛn de gi am we rili simpul kin ɛp fɔ mek di pɔsin kɔntinyu fɔ fala di tritmɛnt.
Dɛn kin yuz GLP-1 bak wit ɔda mɛrɛsin dɛn. we dεn kam togεda wit mεtformin, we na fכs layn mεdikeshכn fכ tayp 2 mεtabolism, i de impruv insulin rεsistεns εn rεdכks hεpatik glukכs autput. Di tu mɛrɛsin dɛn gɛt kɔmplimɛnt mɛkanism fɔ akshɔn, we de mek i ebul fɔ kɔntrol di glukɔs na di blɔd mɔ fayn fayn wan. stכdi dεn sho se dis kכmbaynshכn rεjim de lכs di HbA1c lεvεl mכr εn i de rεsult in mכr pronכns weit lכs. Fɔ ɛgzampul, insay sɔm klinik trayal dɛn, di pasɛnt dɛn we dɛn trit wit mɛtfɔmin we ad GLP-1 bin gɛt big ridɔkshɔn pan HbA1c lɛvɛl kɔmpia to di wan dɛn we kɔntinyu fɔ gɛt mɛtfɔmin monotɛrapi, wit ɔda wet lɔs, we nɔ bin gɛt bɔku inkris pan di risk fɔ di haypoglycemia. Dis rijim fayn fɔ di wan dɛn we dɛn nɔ kin kɔntrol dɛn blɔd glukɔs lɛvɛl fayn fayn wan wit mɛtfɔmin monotɛrapi.
Fɔ di sik pipul dɛn we gɛt tayp 2 mɛtabolism we gɛt ay glukɔs na dɛn blɔd ɛn we nid insulin tɛrapi, fɔ ad GLP-1 to insulin tɛrapi kin ridyus di insulin doz. Insay insulin tritmɛnt, bɔku tɛm di sik pipul dɛn kin gɛt prɔblɛm dɛn lɛk we dɛn de gɛt bɔku bɔku bɔdi ɛn we dɛn kin gɛt bɔku bɔku blɔd blɔd. we dεn yuz am togɛda, di ifekt dεm we GLP-1 de gi fכ mek insulin sekreshכn εn inhibit glukagon sekreshכn kin mek yu yuz insulin fayn fayn wan, ridyus di dכz, εn dat kin mek i lכs di risk fכ weit gεn εn haypoglycemia. Fɔ ɛgzampul, insay sɔm klinik stɔdi dɛm, di pasɛnt dɛm we ad GLP-1 to dɛn insulin tɛrapi bin gɛt avɛrej ridɔkshɔn pan insulin doz, wit mɔ dɛkɛshɔn pan HbA1c lɛvɛl, weit lɔs, ɛn ridɔkshɔn pan di frɛkuɛns fɔ haypoglycemia ɛpisod dɛm.
GLP-1 kin yuz bak wit ɔda antidiabetic drɔgs lɛk SGLT2 inhibito dɛn. SGLT2 inhibito dεm de lכs di blכd glukכs bay we dεn de protεkt di glukכs kכmכt na di urine. di kכmbaynshכn fכ di tu kin impruv bכdi glukכs kכntrכl mכr tru difrεn mεkanism dεm εn i kin gεt sinagεstik ifekt dεm bak pan wet mεnejmεnt.
Di rol we GLP-1 de ple pan wet mɛnejɛmɛnt
Fɔ mek pɔsin nɔ want fɔ it
GLP-1 de akt pan GLP-1 risεptor dεm na di sεntri nεv sεstem, patikyular insay di haypothalamus. di haypothalamus na wan kכl rijyכn na di bכdi fכ rεgεl di apεtit εn εnεji bεlε. afta i biεn di GLP-1 rεsεpכta dεm na di haypothalamus, GLP-1 kin rεgεl di rilis fכ nyuropεptida dεm, lεk fכ ridyus di sekreshכn fכ nyuropεptida Y (NPY), we na strכng apetit-stimulating fכktכ. apat frכm dat, GLP-1 kin inkrεs di aktiviti fכ proopiomelanocortin (POMC) nyuron dεm, we in aktibכshכn de jεnarεt satiety signal dεm. tru dεn mεkanism dεm ya, GLP-1 de sכpres di apεtit fayn fayn wan, we de mek di sik pipul dεm rεdכks di it we dεn de it. Insay klinik trial, di wan dɛn we fat ɔ we gɛt bɔku bɔku bɔdi we de yuz GLP-1 bin ripɔt se dɛn nɔ bin want fɔ it bɛtɛ ɛn dɛn nɔ bin de it bɛtɛ tin fɔ it, we bin le di fawndeshɔn fɔ mek dɛn lɔs dɛn wet.
Di mɔni we dɛn de spɛn pan ɛnaji
apat frכm we i de sכpres di apεtit, GLP-1 kin infכlכ di εnεji mεtabolism bak, we de inkrεs di εnεji we i de spεnd. rεsכch sho se GLP-1 kin inkrεs εnεji εkspεndishכn bay we i de rεgεl di aktiviti fכ brawn adipos tisu. brawn adipose tisu na spεshal tכp fεt tisu we in praymar fכnshכn na fכ kכnsכm enεji tru tεmכjεnεsis. GLP-1 kin aktibכt sכm signal path dεm na brawn adipos tisu, we de protεkt fεt asid כksidεshכn εn tεmכjεnεsis. apat frכm dat, GLP-1 kin infכlכw di enεji mεtabolism insay tisu dεm lεk mכsul, we de inkrεs di enεji we i de spεnd ivin we i de rεst. fכ egzampl, insay animal εkspεriεns, afta dεn gi GLP-1, di animal dεm in enεji mεtabolism rεt inkrεs, εn dεn bכdi wet dכn dכn ivin we di it we dεn de it bin de di sem, we sho se GLP-1 de ple fayn rol fכ mεnejmεnt di wet bay we i de inkrεs di εnεji we dεn de spɛn.
Rεgulεshכn fכ di mεtabolism fכ fεt
GLP-1 gεt rεgεdyushכn ifekt bak pan fεt mεtabolism. I kin mek di fat brok, i kin mek di fat nɔ bɔku, ɛn i kin mek i nɔ ebul fɔ kip di fat. insay di liva, GLP-1 kin inhεbit di aktiviti fכ di εnzym dεm lεk fεt asid sεntez, we de ridyus fεt asid sεntez. apat frכm dat, insay adipos tisu, GLP-1 kin mek di fεt brok dכn, inkrεs di rilis fכ fri fεt asid dεm, εn i kin mek dεn go insay di maytochכndria fכ כksidεtiv brεk dכn, we de mek di fεt stכrej dכn. Klinik stכdi dεn sho se afta wan tεm we dεn trit GLP-1, di pasεnshכn in bכdi fεt, spεshal vishכnal fεt, de dכn. Dis nכto nכmכ de εp fכ lכs di wet bכt i gεt bכku implεkshכn fכ impruv mεtabolik sεndrכm εn ridyus di risk fכ kכdivaskyul sik.
Aplikeshɔn fɔ GLP-1 insay Weyt Manejmɛnt
Fɔ di wan dɛn we fat ɔ we gɛt bɔku bɔku bɔdi we gɛt sik dɛn we gɛt fɔ du wit am
GLP-1 gεt klia tכgεt pכpulεshכn fכ weit mεnejmεnt. Fɔ fat pasɛnt dɛn we gɛt BMI ≥30 kg/m² ɔ pasɛnt dɛn we gɛt bɔku bɔku bɔdi we gɛt BMI ≥27 kg/m² ɛn at le wan sik we gɛt fɔ du wit yu wet (lɛk aypatɛnshɔn, tayp 2 mɛtabolism, ɔ haypa kɔlɔstrelemia), na fayn mɛrɛsin fɔ mɛn yu wet. Di STEP siriɔs klinik trayal dɛn sho se di wan dɛn we dɛn trit dɔn lɔs bɔku bɔku wet. Insay di STEP 1 stɔdi, di pasɛnt dɛn we dɛn trit bin ajɔst wan avɛj wet lɔs we na lɛk 15% ova 68 wik, we di plesibo grup bin lɔs lɛk 2.4% nɔmɔ. Dɛn rizɔlt ya sho se i kin ɛp di wan dɛn we fat ɔ we gɛt bɔku bɔku bɔdi we gɛt prɔblɛm dɛn we gɛt fɔ du wit dis, fɔ mek dɛn nɔ gɛt bɔku bɔku bɔdi ɛn fɔ lɔng tɛm, i kin mek dɛn gɛt wɛlbɔdi, ɛn i kin mek dɛn nɔ gɛt bɔku sik dɛn we gɛt fɔ du wit dɛn we dɛn fat.
Kɔmbayn wit layf stayl intavɛnshɔn
insay weit mεnejmεnt, dεn kin yuz GLP-1 in kכmbaynshכn wit layf stayl intavεnshכn, inklud fכ ridyus kalori intake εn inkrεs fכshal aktiviti. If fɔ lɛf fɔ it bɔku bɔku it de dipen pan mɛrɛsin nɔmɔ ɛn nɔ chenj di we aw pɔsin de liv in layf we nɔ fayn, bɔku tɛm di tin dɛn we kin apin nɔ kin kɔntinyu fɔ de. di kכmbaynshכn fכ di tu we dεm gεt wan sinajεstik ifekt: di mεdikeshכn de sכpres di apεtit εn i de inkrεs di εnεji we yu de spεnd, we di it kכntrכl de rεdכks di kalori we yu de it εn inkrεs fכshal aktiviti de bכst di εnεji mכr, we de mek yu lכs mכr signifyant εn sustained weit. Fɔ ɛgzampul, insay sɔm klinik prɔsis, pasɛnt dɛn we de fala wan lɔw-kalori it plan we wan nyutrishɔnist dɔn mek ɛn inkrisayz dɛn wik aerobic ɛksɛsayz tɛm we dɛn de gɛt tritmɛnt kin gɛt bɛtɛ bɛtɛ wet lɔs autkam pas di wan dɛn we de abop pan mɛrɛsin ɔ layf stayl intavɛnshɔn nɔmɔ. Dis kɔmbayn we fɔ du tin de ɛksplen di impɔtants fɔ kɔmprɛhnsiv mɛnejɛmɛnt insay di wet mɛnejɛmɛnt, fɔ ɛp di sikman dɛn fɔ mek dɛn gɛt wɛlbɔdi layf ɛn fɔ ebul fɔ kɔntrol dɛn wet fɔ lɔng tɛm.
Dɔn
GLP-1 de sho signifyant pכtεnshal in כl tu di mεtabolism tritmεnt εn weit mεnejmεnt. insay mεtabolism tritmεnt, i de kכntro di bכdi glukכs fayn fayn wan tru mכltipכl mεkanism dεm, i de mek β-sεl dεm fכ wok fayn, εn dεn kin yuz am as mכno tεrapi כ in kכmbaynshכn wit כda antidiabetic mεdikeshכn dεm. Insay di wet mɛnejɛmɛnt, i de stɔp di apɛtit, i de mek yu spɛn mɔ ɛnaji, ɛn i de rigul di fat mɛtabolism, we de mek i fayn fɔ di wan dɛn we fat ɔ we gɛt bɔku bɔku bɔdi we gɛt di sik dɛn we gɛt fɔ du wit am. We dɛn put am togɛda wit di tin dɛn we pɔsin kin du fɔ liv in layf, i kin mek i gɛt bɛtɛ tin fɔ du.
Sos dɛn we dɛn pul
[1] Salvador R, Moutinho CG, Sousa C, ɛn ɔda pipul dɛn. GLP-1 as a GLP-1 Agonist: Wan Brekthrough in Obesity Tritmεnt[J]. Famasiutik, 2025,18(3).DOI:10.3390/ph18030399.
[2] Memon A, Tehrim M, Kumari B. GLP-1: nyu dawn fɔ di wan dɛn we gɛt dayabitis[J]. J ɔ rnal ɔ f di Pakistan Mɛdikal Assosiayshɔn, 2023,73(3):721.DOI:10.47391/JPMA.7558.
[3] Colin IM, Gérard K M. Wans-wik 2.4 mg GLP-1 fכ Weyt Mεnejmεnt in Obesiti: Wan Gεm Chenj?[J]. Touchrev Ɛndokrinɔl, 2022,18(1):35-42.DOI:10.17925/EE.2022.18.1.35.
[4] Singh G, Krauthamer M, Bjalme-Evans M. Wegovy (GLP-1): wan nyu weit lכs drog fכ krכnik wet mεnejmεnt[J]. J ɔ rnal ov Inv ɛ stigetiv Mɛdisin, 2022,70(1):5-13.DOI:10.1136/jim-2021-001952.
[5] Mares AC, Chatterjee S, Mukherjee D. GLP-1 fכ weit lכs εn kכdiכmεtabolik risk rεdukshכn in כvaweit/obesiti[J]. Kɔrɛnt Opinion in Kadiɔlɔji, 2022,37(4):350-355.DOI:10.1097/HCO.0000000000000955.
[6] Chudleigh RA, Bain S C. GLP-1 injεkshכn fכ di tritmεnt fכ big pipul dεm wit tayp 2 mεtabolism[J]. Ekspɛkt Rivyu fɔ Klinik Famakɔlɔji, 2020,13(7):675-684.DOI:10.1080/17512433.2020.1776108.
[7] Gomez-Peralta F, Abreu C. Profayl fכ GLP-1 in di mεnejmεnt fכ tayp 2 mεtabolism: disayn, divεlכpmεnt, εn ples in tεrapi[J]. Drug Des Dɛvɛl Tɛr, 2019,13:731-738.DOI:10.2147/DDDT.S165372.
[8] Hedrington MS, Davis S N. Oral GLP-1 fכ di tritmεnt fכ tayp 2 mεtabolism[J]. Ekspɛkt Opinion Pan Famakotɛrapi, 2019,20(2):133-141.DOI:10.1080/14656566.2018.1552258.
Prodak we de fɔ yuz fɔ risach nɔmɔ:
